

## Submission Data File

| General Information       |                              |
|---------------------------|------------------------------|
| Form Type*                | 6-K                          |
| Contact Name              | M2 Compliance                |
| Contact Phone             | 754-243-5120                 |
| <b>Filer File Number</b>  |                              |
| Filer CIK*                | 0001849296 (OKYO Pharma Ltd) |
| Filer CCC*                | *****                        |
| Confirming Copy           | No                           |
| Notify via Website only   | No                           |
| Return Copy               | Yes                          |
| SROS*                     | NONE                         |
| Period*                   |                              |
| (End General Information) |                              |

| Document Information          |             |
|-------------------------------|-------------|
| File Count*                   | 2           |
| Document Name 1*              | form6-k.htm |
| Document Type 1*              | 6-K         |
| <b>Document Description 1</b> |             |
| Document Name 2*              | ex99-1.htm  |
| Document Type 2*              | EX-99.1     |
| <b>Document Description 2</b> |             |
| (End Document Information)    |             |

| Notifications           |                         |
|-------------------------|-------------------------|
| Notify via Website only | No                      |
| E-mail 1                | filing@m2compliance.com |
| (End Notifications)     |                         |

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**May 2023**

---

**Commission File Number: 001-41386**

---

**OKYO Pharma LTD**

(Exact Name of Registrant as Specified in Its Charter)

---

**9<sup>th</sup> Floor  
107 Cheapside  
London  
EC2V 6DN**

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On May 3, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing Result of General Meeting, a copy of which is furnished as Exhibit 99.1

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**OKYO Pharma LTD**

Date: May 3 2023

By: /s/ Keeren Shah

Name: Keeren Shah

Title: Chief Financial Officer

**EXHIBIT INDEX**

| <b>Exhibit No.</b> | <b>Description</b>                                   |
|--------------------|--|
| 99.1               | <a href="#">News Announcement, dated May 3, 2023</a> |

---

4

---

**Exhibit 99.1**

3 May 2023

**OKYO Pharma Limited**  
**(“OKYO” or “Company”)**  
**Result of General Meeting**

The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that at the General Meeting (“GM”) of the Company held earlier today all resolutions were duly passed.

The result of the poll, including the proxy voting, is as follows:

| Resolution | Description                  | For         |                    | Against |                    | Discretion |                    | Withheld | Total Votes<br>Cast (excl.<br>Votes<br>Withheld) | For + discretion |                    |
|------------|------------------------------|-------------|--------------------|---------|--------------------|------------|--------------------|----------|--|------------------|--------------------|
|            |                              | Votes       | %<br>Votes<br>Cast | Votes   | %<br>Votes<br>Cast | Votes      | %<br>Votes<br>Cast |          |  | Votes            | %<br>Votes<br>Cast |
| RES:001    | SHARE<br>CONSOLIDATION       | 545,538,277 | 99.93              | 375,103 | 0.07               | 32,915     | 0.006              | 60,371   | 545,946,295                                      | 545,571,192      | 99.93              |
| RES:002    | DIRECTORS TO<br>ALLOT SHARES | 545,533,344 | 99.92              | 378,836 | 0.07               | 32,915     | 0.006              | 61,571   | 545,945,095                                      | 545,566,259      | 99.93              |
| RES:003    | PRE-EMPTION<br>RIGHTS        | 545,527,392 | 99.92              | 384,788 | 0.07               | 32,915     | 0.006              | 61,571   | 545,945,095                                      | 545,560,307      | 99.93              |
| RES:004    | AMENDMENT TO<br>ARTICLES     | 545,327,392 | 99.93              | 375,103 | 0.07               | 32,915     | 0.006              | 71,256   | 545,735,410                                      | 545,360,307      | 99.93              |

**Further information on votes:**

As at 2 May 2023, there were 1,658,792,349 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.

The resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant deadline, together with those cast at the GM itself, and will be available on the National Storage Mechanism, <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The result of poll and proxy voting will also be available on the Company’s website, [www.okyopharma.com](http://www.okyopharma.com).

**Enquiries:**

|   |  |                     |
|---|--|---------------------|
| <b>OKYO Pharma Limited</b>                    | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
| <b>Investor Relations</b>                     | Paul Spencer                           | +44 (0)20 7495 2379 |
| <b>Optiva Securities Limited<br/>(Broker)</b> | Robert Emmet                           | +44 (0)20 3981 4173 |